Ivabradine in Heart Failure

Authors: Prakash C Deedwania

Publish Date: 2012/12/29

Volume: 12, Issue: 6, Pages: 357-359

PDF Link

Abstract

During the past two decades considerable progress has been made in understanding the pathophysiology of heart failure HF and subsequent development of several therapeutic agents primarily based on the neurohormonal blockade with reninangiotensinaldosterone system RAAS blocking agents eg angiotensionconverting enzyme inhibitors ACEIs angiotensin II receptor blockers ARBs and aldosterone receptor blockers and βblockers1 Although these drugs are highly effective in reducing the morbidity and mortality in HF there is considerable residual risk that remains despite appropriate use of these agents Ivabradine which is a specific heart rate HRlowering agent that acts by inhibiting funny channels If a key ‘pacemaker’ current in the sinoatrial node has recently been shown to be effective in the treatment of patients already receiving guidelinebased therapy with RAAS blocking agents and βblockers bringing new hope of further reducing the residual risk of

Keywords: